Navigation Links
InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
Date:2/3/2009

amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. The top-line efficacy, safety and tolerability data reported in this press release are from analyses of the highest areas of interest to the company based on the prior clinical experience with pirfenidone in IPF patients. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon the efficacy data from a single pivotal trial, in combination with the other efficacy and safety results the company currently intends to submit in support of its NDA and MAA filings. Further analyses of the CAPACITY results will be conducted in the future and additional observations may be made which may lead to material change in the company's current regulatory strategy for pirfenidone, including a decision by the company not to proceed with either or both of its regulatory submissions in the United States and Europe. These analyses and observations will be included in a presentation of the CAPACITY data that the company expects to make at the American Thoracic Society (ATS) in the second quarter of 2009, and/or in a scientific publication. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk
'/>"/>
SOURCE InterMune
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at J.P. Morgan Healthcare Conference
2. InterMune to Present at Deutsche Bank Biotech Boston Confab
3. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
4. InterMune to Release Third Quarter 2008 Financial Results on November 6
5. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
6. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
7. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
8. InterMune to Present at Canaccord Adams Conference
9. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
10. InterMune to Present at BMO Healthcare Conference
11. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... , ... Production of high tenacity filament yarn of viscose rayon (excluding sewing ... instance, it surpassed the EUR 106 million mark (in value terms) in 2013, while ... major producer, while Italy is a key consumer. , The high tenacity filament ...
(Date:7/27/2015)... , July 27, 2015 According ... by Type (Home-brew Media, Pre-formulated Media), by Application (Biobanking, Regenerative ... , Europe , Asia-Pacific ... 2019", The global biopreservation media market was valued at $247.7 ... $571.5 million by 2019, at a CAGR of 18.2% between ...
(Date:7/26/2015)... (PRWEB) , ... July 26, 2015 , ... ... of its VALIDATE® ANEMIA calibration verification / linearity test kit. The VALIDATE® ANEMIA ... Each VALIDATE® ANEMIA kit is prepared using the CLSI recommended “equal delta” method ...
(Date:7/24/2015)... , July 24, 2015  Champions Oncology (OTC-BB: CSBR), ... solutions and services to personalize the development and use ... financial and operational results for the fourth quarter and ... July 28, 2015, before market open. The ... results that day at 9:00 a.m. EDT (6:00 a.m. ...
Breaking Biology Technology:High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2Champions Oncology to Announce Fourth Quarter Financial Results on Tuesday, July 28 2
... April 25 Kosan Biosciences,Incorporated (Nasdaq: KOSN ) ... May 1, 2008, after market close., The announcement ... by a conference call and live webcast on May ... Interested parties may access the live,call by dialing 888.680.0878 ...
... and Collaborators Publish Study in Science, ... GmbH, the,leading developer of RAFT intervention therapeutics, ... Science demonstrating a potential novel strategy,for therapeutic ... targeting,discrete sub-compartments in the cell membrane (RAFTS). ...
... Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today that the ... Conference on May 1, 2008 at,approximately 4:20 p.m. Eastern ... may be accessed through a link on the investors ... will be,available for 30 days following the event., ...
Cached Biology Technology:Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results 2Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 2Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 3Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 4Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference 2
(Date:7/13/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... method to make payments.  With this patent, NXT-ID ... its groundbreaking voice-direct payment patent application, with behavior-directed ...
(Date:7/9/2015)... , July 07, 2015 ... the addition of the "Biometrics for Banking; ... 2015-2020" report to their offering. ... contributor to this growth and the forecast is ... in revenue for companies involved in delivering biometric ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... center called the National Resource for Network Biology (NRNB), ... of Medicine, will help clinicians analyze an ever-growing wealth ... real problems and diseases. In recent years, ... shifting much of their focus from single cells to ...
... PORTLAND, Ore. Oregon Health & Science University Doernbecher ... landmark clinical trial to further assess the safety and ... as a potential treatment for infantile or late-infantile neuronal ... disorder that affects infants and children. The Phase ...
... 28 October 2010 (Geneva, Switzerland) - A report issued ... Here, Right Now documents the principal debates around ... The report also takes stock of progress to date and ... and prevention at a time when new infections are outstripping ...
Cached Biology News:New center looks at how human systems function or fail 2New center looks at how human systems function or fail 3OHSU Doernbecher Children's Hospital conducts second phase of landmark Batten study 2New report underlines the threat to universal access to HIV prevention, treatment and care due to a slow-down in treatment scale-up and waning political will 2New report underlines the threat to universal access to HIV prevention, treatment and care due to a slow-down in treatment scale-up and waning political will 3
... Yeast Cells are designed for use with ... cerevisiae strain MaV203 contains deletions in the ... with GAL4-based two-hybrid systems. The strain also ... of ProQuest bait and prey vectors. MaV203 ...
... designed for use with the ProQuest Two-Hybrid ... contains deletions in the endogenous GAL4 and ... systems. The strain also has leu2 and ... and prey vectors. MaV203 contains three GAL4 ...
Request Info...
... protein in 200 l SDS-PAGE Western blotting buffer, ... transformed macrophage cells, whole cell ... should be stored at -20C and ... sample vial should be boiled once ...
Biology Products: